文献速递癫痫

依维莫司长期治疗结节性硬化症癫痫

Long-term treatment of epilepsy with everolimus in tuberous sclerosis.
PubMed 文献 · Neurology · 2016-11-04

这项前瞻性开放标签I/II期临床试验评估依维莫司治疗结节性硬化症(TSC)药物难治性癫痫的长期获益与安全性。所有参与者至少发生1例不良事件,绝大多数(94%)为轻中度;行为和生活质量改善在48个月时未达统计学显著。

要点

  • 依维莫司可使多数TSC难治性癫痫患者发作频率较基线减少≥50%并维持4年。
  • 长期治疗安全性可接受,所有不良事件中94%为轻中度。
  • 行为和生活质量改善在48个月时未达统计学显著。

核心结论

  • 多数TSC药物难治性癫痫患者接受依维莫司后癫痫控制改善可维持4年。
  • 依维莫司在该人群中长期治疗安全且耐受性良好。
  • 依维莫司可能成为TSC难治性癫痫的治疗选择。

研究设计与样本

  • 前瞻性、开放标签、I/II期临床试验设计。
  • 依维莫司滴定4周并继续治疗额外8周。
  • 初始获益的参与者继续治疗至研究完成(48个月)。
  • 20例完成初始研究阶段,18例继续延长治疗。

主要发现

  • 所有参与者报告至少1例不良事件,其中94%为轻中度。
  • 行为和生活质量改善在48个月时未达统计学显著。

关键数值与推荐

  • 主要终点为癫痫发作频率较基线减少≥50%的患者比例。
  • 次要终点评估绝对发作频率、不良事件、行为和生活质量。
  • 证据等级为Class IV,提示依维莫司改善TSC难治性癫痫患者的癫痫控制。

临床怎么用

  • 对TSC药物难治性癫痫患者,依维莫司可作为长期治疗选项之一。
  • 治疗期间需监测不良事件,但多数为轻中度。
  • 行为和生活质量的获益尚不确定。

局限性

  • 研究为开放标签设计,无对照组。
  • 样本量小,完成延长治疗者仅18例。
  • 行为和生活质量改善未达统计学显著。
  • 证据等级为Class IV。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the long-term benefit and safety of everolimus for the treatment of medically refractory epilepsy in patients with tuberous sclerosis complex (TSC). METHODS: Everolimus was titrated over 4 weeks and continued an additional 8 weeks in a prospective, open-label, phase I/II clinical trial design. Participants demonstrating initial benefit continued treatment until study completion (48 months). The primary endpoint was percentage of patients with a ≥50% reduction in seizure frequency compared to baseline. Secondary endpoints assessed absolute seizure frequency, adverse events (AEs), behavior, and quality of life. RESULTS: Of the 20 participants who completed the initial study phase, 18 continued extended treatment. Fourteen of 18 (78%) participants completed the study, all but 1 of whom reported ≥50% reduction in seizure frequency at 48 months. All participants reported at least 1 AE, the vast majority (94%) of which were graded mild or moderate severity. Improvements in behavior and quality of life were also observed, but failed to achieve statistical significance at 48 months. CONCLUSIONS: Improved seizure control was maintained for 4 years in the majority of patients with TSC with medically refractory epilepsy treated with everolimus. Long-term treatment with everolimus is safe and well-tolerated in this population. Everolimus may be a therapeutic option for refractory epilepsy in TSC. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with TSC with medically refractory epilepsy everolimus improves seizure control.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Krueger DA, Wilfong AA, Mays M, et al. Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology. 2016. PMID: 27815402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。